

***Fiscal Year 2013 Neurofibromatosis Research Program (NFRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Clinical Trial Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">W81XWH-13-NFRP-CTA</a></p>	<p>Must be an independent investigator <i>at or above</i> the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> <li>• Funds Phase 0, I, or II clinical trials relevant to NF and/or schwannomatosis. Combinations of phases are permitted.</li> <li>• <b><i>Preclinical data required.</i></b></li> <li>• Phase I or pilot clinical trial data required for Phase II clinical trial applications.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is <b>4</b> years.</li> <li>• The maximum allowable funding for the entire period of performance is <b>\$900,000</b> in direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-application (Letter of Intent):</b> June 27, 2013 5:00 p.m. Eastern time (ET)</p> <p><b>Application:</b> July 11, 2013 11:59 p.m. ET</p>
<p><b>Exploration – Hypothesis Development Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">W81XWH-13-NFRP-EHDA</a></p>	<p>All levels of experience.</p>	<ul style="list-style-type: none"> <li>• Funds the initial exploration of innovative, untested research and pursue serendipitous observations.</li> <li>• <b><i>Preliminary data encouraged but not required.</i></b></li> <li>• Projects involving human subjects or human anatomical substances must be exempt under 32 CFR 219.101(b) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.</li> <li>• Clinical trials not allowed.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is <b>2</b> years.</li> <li>• The maximum allowable funding for the entire period of performance is <b>\$100,000</b> in direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-application (Letter of Intent):</b> June 27, 2013 5:00 p.m. ET</p> <p><b>Application:</b> July 11, 2013 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Investigator-Initiated Research Award</b></p> <p>Go to:</p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">W81XWH-13-NFRP-IIRA</a></p>	<p><b>Principal Investigator (PI):</b> Must be an independent investigator <i>at or above</i> the level of Assistant Professor (or equivalent).</p> <p><b>Optional Qualified Collaborator:</b> Must be <i>at or above</i> the level of Assistant Professor (or equivalent).</p> <p><b>Optional Nested Postdoctoral Traineeship:</b> Must have 5 years or less of postdoctoral experience at the time of application.</p>	<ul style="list-style-type: none"> <li>• Funds basic and clinically oriented research relevant to NF and/or schwannomatosis.</li> <li>• <b>Preliminary data required.</b></li> <li>• <b>Optional Features:</b> Applications that include either a Qualified Collaborator <i>or</i> Postdoctoral Fellow who meet criteria identified in the Program Announcement/Funding Opportunity may apply for a higher level of funding.</li> <li>• Clinical trials not allowed.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is <b>3</b> years.</li> <li>• The maximum allowable funding for the entire period of performance is <b>\$525,000</b> in direct costs (<b>\$575,000</b> in direct costs if requesting an Optional Qualified Collaborator <i>or</i> <b>\$675,000</b> in direct costs if requesting an Optional Nested Postdoctoral Fellow).</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-application (Letter of Intent):</b> June 27, 2013 5:00 p.m. ET</p> <p><b>Application:</b> July 11, 2013 11:59 p.m. ET</p>
<p><b>New Investigator Award</b></p> <p>Go to:</p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">General Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> <a href="#">W81XWH-13-NFRP-NIA</a></p>	<p>Must be either an independent investigator <i>at or below</i> the level of Assistant Professor (or equivalent) <i>or</i> an established independent investigator in an area other than NF <i>at or above</i> the level of Assistant Professor seeking to transition into a career in NF research.</p> <p>To be eligible, applicants may not have received more than \$300,000 in direct costs for NF research as a PI of one or more federally funded, non-mentored peer reviewed grants.</p>	<ul style="list-style-type: none"> <li>• Fund investigators in the early stages of their careers or established investigators seeking to transition into a career in NF research.</li> <li>• Experience in NF research is allowed, but not required.</li> <li>• <b>Preliminary data required.</b></li> <li>• Clinical trials not allowed.</li> </ul>	<ul style="list-style-type: none"> <li>• The maximum period of performance is <b>3</b> years.</li> <li>• The maximum allowable funding for the entire period of performance is <b>\$400,000</b> in direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-application (Letter of Intent):</b> June 27, 2013 5:00 p.m. ET</p> <p><b>Application:</b> July 11, 2013 11:59 p.m. ET</p>